Resistance to chemotherapy represents a major obstacle for long-term remission, and effective strategies to overcome drug resistance would have significant clinical impact. We report that recurrent ovarian carcinomas after paclitaxel/carboplatin treatment have higher levels of spleen tyrosine kinase (SYK) and phospho-SYK. In vitro, paclitaxel-resistant cells expressed higher SYK, and the ratio of phospho-SYK/SYK positively associated with paclitaxel resistance in ovarian cancer cells. Inactivation of SYK by inhibitors or gene knockdown sensitized paclitaxel cytotoxicity in vitro and in vivo. Analysis of the phosphotyrosine proteome in paclitaxel-resistant tumor cells revealed that SYK phosphorylates tubulins and microtubule-associated proteins. Inhibition of SYK enhanced microtubule stability in paclitaxel-resistant tumor cells that were otherwise insensitive. Thus, targeting SYK pathway is a promising strategy to enhance paclitaxel response.
In Brief Yu et al. show that ovarian cancer cells surviving paclitaxel treatment have higher levels of activated spleen tyrosine kinase (SYK). Importantly, inhibition of SYK sensitizes ovarian cancer cells to paclitaxel treatment via enhancing microtubule stability.
INTRODUCTION
Development of resistance to chemotherapeutic agents is a prevalent and challenging problem in managing cancer (Holohan et al., 2013) . The high morbidity and mortality associated with many types of human cancer are attributed to the emergence of tumor cells that are refractory to cytotoxic chemotherapy and clonally develop into recurrent tumors. Although The Cancer Genome Atlas and several other genome-wide studies have revealed the molecular landscapes of cancer, these studies mainly focus on primary tumors (Vogelstein et al., 2013) . It is critical, however, to study recurrent tumors and elucidate the molecular etiology of drug resistance. Toward this goal, we previously studied ovarian high-grade serous carcinoma (HGSC) to identify genes and the pathways they controlled in the development of recurrent disease. HGSC is the most common and lethal type of ovarian cancer (Cho and Shih, 2009) ; most patients are diagnosed with advanced-stage disease and require first-line
Significance
There is an unmet need to introduce more effective drugs to enhance therapeutic effects of current chemotherapeutic agents. Here, we demonstrated that inactivating spleen tyrosine kinase (SYK) using small compound inhibitors sensitized cells to the cytotoxic effects of paclitaxel, overcoming paclitaxel resistance. We found that SYK inhibitors stabilized microtubules through dephosphorylation of microtubule and microtubule-associated proteins, a mechanism that is distinct from paclitaxel. As a result, SYK inhibitor and paclitaxel formed a synergistic cytotoxic effect in tumor cells, especially in those that were paclitaxel-resistant. Our results provide critical pre-clinical evidence proposing the use of SYK inhibitors in combination with paclitaxel in cancer patients, and warrant future clinical studies to assess the clinical benefit of such combined therapy. therapy, which involves cytoreductive surgery followed by combined carboplatin and paclitaxel chemotherapy. Although HGSC generally responds to this standard chemotherapy at the beginning of its course, relapse usually occurs and requires further therapy including the weekly paclitaxel regimen. Unfortunately, only a small percentage (10%-15%) of patients with advanced disease achieve long-term remission.
In a previous study, we compared proteomes between primary and recurrent post-chemotherapy HGSC tissues from the same patients (Jinawath et al., 2010) . Among the preferentially expressed proteins identified in recurrent HGSCs, the non-receptor tyrosine kinase, spleen tyrosine kinase (SYK), was of interest because more than half of the recurrent tumors expressed higher levels of SYK than did the primary tumors (Jinawath et al., 2010) . This is significant because small molecule inhibitors that target SYK, such as fostamatinib (R788), are available for preclinical testing and for future clinical trials in patients with ovarian cancer (Ruzza et al., 2009) .
Originally isolated from bovine thymus (Zioncheck et al., 1986 ) and later identified in activated B lymphocytes (Hutchcroft et al., 1991; Zioncheck et al., 1988) , SYK regulates adaptive immune receptor signaling, cell proliferation, differentiation, and survival. SYK has been reported as a candidate oncogene in B cell leukemia and lymphomas, gastric carcinoma, and head and neck cancer (Buchner et al., 2009; Feldman et al., 2008; Luangdilok et al., 2007; Mó csai et al., 2010; Nakashima et al., 2006) . SYK expression has an anti-apoptotic effect on B-lymphoma cell lines through phosphorylation of nucleolin, which stabilizes the mRNA of anti-apoptotic Bcl-x(L) (Wang et al., 2014) . Paradoxically, SYK expression may block tumor progression in breast cancer because loss of its expression is associated with poor prognosis and tumor metastasis (Coopman et al., 2000) . The evidence thus suggests that SYK can either negatively or positively regulate tumor progression, depending on the biological context and tissue lineage (Geahlen, 2014) .
The purpose of this study is to determine how SYK contributes to chemoresistance in ovarian cancers and to establish a biological foundation for introducing SYK inhibitors to potentiate the anti-tumor effects of chemotherapeutic drugs. We also seek to identify candidate SYK substrates involved in drug resistance, and the results should have translational implications to improve chemotherapy and clinical outcomes in patients with cancer.
RESULTS

Recurrent Ovarian Tumors Express Higher Levels of SYK and Phosphorylated SYK
To compare the expression levels of SYK in paired recurrent post-chemotherapy ovarian HGSC and their primary untreated tumors, we performed immunohistochemistry using two antibodies, one specific for SYK and the other specific for its active (autophosphorylated) form, p-SYK (Y525/526). Using the H score to semi-quantify immunoreactivity, we found that H scores for SYK were higher in the recurrent ovarian HGSC specimens than in the primary counterparts ( Figure 1A) , and H scores for active p-SYK (Y525/526) were higher in recurrent tumors than in primary tumors ( Figure 1B) . Likewise, H scores of total SYK or p-SYK positively correlated to each other ( Figure 1C ). Representative staining for p-SYK in a pair of matched primary and recurrent ovarian HGSC is shown in Figure 1D . Aside from HGSC, upregulated SYK expression was also observed in four of six cases of recurrent post-chemotherapy ovarian clear cell carcinomas as compared to matched primary tumors (Figure S1A) . We further examined SYK expression using immunohistochemistry in 214 serous ovarian carcinoma effusions (Table  S1 ; see the Supplemental Experimental Procedures for the cohort information) and observed an association (p = 0.005) between higher SYK staining intensity and less favorable chemoresponse to paclitaxel/platinum-based combination therapy. These data support that SYK upregulation is associated with chemoresistance.
Association between Paclitaxel Resistance and SYK Because the recurrent HGSC tissues were obtained from patients who were previously treated with carboplatin and paclitaxel combination therapy, we sought to determine if SYK overexpression was related to resistance of carboplatin or paclitaxel. We analyzed two ovarian cancer cell lines, SKOV3 and MPSC1, from which carboplatin resistant and paclitaxel-resistant (TR) clones were previously established (Jinawath et al., , 2010 . We found that paclitaxel-resistant SKOV3TR and MPSC1TR expressed higher levels of SYK and p-SYK (Y525/ 526) than the parental cells ( Figures 1E and 1F ), suggesting that SYK upregulation was related to biological resistance to paclitaxel and is unlikely due to acute induction by paclitaxel in naive cells ( Figure S1B ).
To examine if there is an association between SYK activity and response to paclitaxel, we analyzed a panel of 25 primary ovarian cancer cell cultures and cell lines expressing different levels of SYK by immunoblotting ( Figure S1C ). The degree of paclitaxel sensitivity in these cells was determined by their half-maximal inhibitory concentration (IC 50 ) values. A significant positive correlation was observed between p-SYK/SYK ratios and the IC 50 of paclitaxel but not carboplatin ( Figure 1G ), suggesting that active SYK is an important determinant of paclitaxel resistance.
Inactivation of SYK Suppresses Cell Growth in Ovarian Cancer Cells
To determine if SYK can be a therapeutic target in ovarian cancer, we inactivated SYK using shRNAs or small molecule inhibitors. We found that SYK knockdown, as compared to control knockdown, significantly reduced cell numbers in naive (parental) SKOV3 and MPSC1 as well as in their corresponding paclitaxel-resistant clones, although the SYK knockdown achieved in resistant cells was not as pronounced as in the naive cells ( Figure 2A ). Next, we treated SKOV3 cells with the SYK inhibitor R406 (the active metabolite of fostamatinib) and observed that R406 suppressed SYK autophosphorylation at Y525/526 and Y352, which was considered an indicator for SYK activation ( Figure 2B ) and resulted in concentration-dependent inhibition of SYK activity as measured by reduction of p-SYK (Y525/526) (Figure S2A) . We further observed that R406 inhibited proliferation in a dose-dependent manner in SKOV3, SKOV3TR, MPSC1, and MPSC1TR cells ( Figure 2C ).
Next, we determined the sensitivity to R406 in a panel of cell lines with various levels of endogenous SYK expression (Figure 2D ). Based on western blot analysis, we separated cell lines into SYK-expressing and undetectable groups and observed significantly greater sensitivity to R406 (lower IC 50 values) in SYK-expressing cell lines than in cell lines with undetectable levels of SYK expression ( Figure 2E ). Calculation of Spearman's rank correlation coefficient demonstrated a negative correlation between SYK expression and the IC 50 values for R406 (Figure 2F) . Similarly, an inverse correlation between p-SYK (Y525/ 526) expression levels and the IC 50 values of R406 was observed in these cell lines ( Figure S2B ).
SYK Inhibitors Enhance Paclitaxel Sensitivity
We then tested the effect of combining R406 with chemotherapeutic agents including paclitaxel, docetaxel, carboplatin, 5-fluorouracil, doxorubicin, mitomycin C, and methotrexate. Based on the drug combination index, we found that microtubule-targeting agents, including paclitaxel and docetaxel, had a synergistic effect with R406, whereas other drugs, including carboplatin, produced no such effect ( Figures 3A and S3A ). The ability of SYK inhibitor to enhance paclitaxel cytotoxicity was dose dependent because higher R406 concentrations were associated with a greater inhibitory effect ( Figure 3B ). Enhancement of paclitaxel sensitivity was also observed by SYK knockdown using shRNAs (Figures S3B and S3C) and siRNAs (Figures S3D and S3E) . In other primary ovarian tumor cell cultures and ovarian cancer cell lines that exhibited high intrinsic resistance to paclitaxel (IC 50 R 5 nM), the combination (A and B) Immunohistochemistry shows levels of SYK (A) and phospho-SYK (p-SYK, Y525/526) (B) in recurrent ovarian HGSCs compared to primary untreated specimens from the same patients based on paired two-tailed t test (n = 23 pairs). H score is used to semi-quantify the expression levels. The bottom and top of the boxplots represent the first and third quartiles, the band inside the box is the median, and the lines above and below the box indicate the maximum and minimum of all of the data. Figure S1 and Table S1. of paclitaxel and SYK inhibitors was also synergistic ( Figure 3D ; Figure S3F ). The use of other SYK inhibitors including P505-15/PRT062607 and GS-9973 (Figure 3C ) (Currie et al., 2014; Hoellenriegel et al., 2012) produced a similar result. In cell lines with high levels of SYK, including OVCAR3 and OVCA429, the same synergistic effect was also observed (Figure S3F) . These data suggest that the effect observed from R406 was unlikely due to non-specific pan-kinase inhibition.
The effect of R406 on paclitaxel-induced cytotoxicity was further compared between paclitaxel-resistant and -naive cells. We found that treatment with SYK inhibitors resulted in a prominent shift of the paclitaxel IC 50 s in both SKOV3TR and MPSC1TR cells compared to parental SKOV3 and MPSC1 cells. Specifically, the ratio of paclitaxel IC 50 in untreated to R406 treated SKOV3 cells was 2.5, whereas in SKOV3TR it was 236 ( Figure 3E ). The ratio of paclitaxel IC 50 for MPSC1 cells in untreated cells to R406 treated cells was 8, whereas in MPSC1TR it was 12,429 ( Figure 3F ), suggesting that paclitaxel-resistant cells were much more sensitive to the combined SYK inhibitor and paclitaxel treatment than their parental counterparts. The other SYK inhibitors also showed synergistic relationship with paclitaxel in the resistant SKOV3TR and MPSC1TR cells ( Figure S3F ).
Combination of R406 and Paclitaxel Induces G2/M Arrest and Enhances Apoptosis Because paclitaxel targets microtubules, the above results suggested that SYK may also regulate microtubule function, which is essential for mitosis. Therefore, we quantified cell cycle Paclitaxel (nM) % cell survival distribution in cells treated with R406, paclitaxel, or their combination. It is known that paclitaxel induces microtubule stabilization and leads to mitotic block in the late G2/M phase of the cell cycle. Based on high-throughput imaging analysis of in vitro cell cultures using Hoechst 33342 staining of DNA, we were able to confirm that paclitaxel increased the fraction of SKOV3 cells at the G2/M phase 8 hr, 12 hr, or 16 hr after treatment ( Figures  S3G and S3H ). In contrast, SKOV3TR cells did not respond to paclitaxel treatment alone, but arrested in G2/M phase only when the cells were co-treated with R406. In addition, the levels of apoptosis markers, cleaved PARP, and caspase 7 ( Figure S3I ) and annexin V staining ( Figure S3J ) increased when cells were co-treated with R406 and paclitaxel compared to the cells treated with vehicle control, R406, or paclitaxel only.
Combination of R406 and Paclitaxel Inhibits Tumor Growth in Naive and Paclitaxel-Resistant Ovarian Tumor Xenograft Two mouse models were used to assess the anti-tumor effect of R406, paclitaxel, and the combination. In the first model, SKOV3c.2 cell line was used because this subclone of SKOV3 was tumorigenic subcutaneously and expressed a relatively higher level of SYK ( Figure 2D ). Athymic mice bearing the SKOV3c.2 subcutaneous tumors were treated with paclitaxel (8 mg/kg), R406 (6.5 mg/kg), or the combination. Drugs were administered over several 3 days on/3 days off cycles initiated when the tumors first became palpable ( Figure S4A ). We intended to use a low dose of paclitaxel and R406 to determine the combinational anti-tumor effect and minimize adverse effects. At the given doses, there was no significant difference in tumor weight between the control group and the groups treated with either single R406 or paclitaxel after four cycles of treatment ( Figures  4A-4C ). However, a significant reduction in tumor weight was recorded in the group co-treated with R406 and paclitaxel compared to the control group (p < 0.0004). The percentage of tumor cells that incorporated bromodeoxyuridine (BrdU) was significantly lower in tumors receiving the combined R406 and paclitaxel than in other groups (p = 0.01) ( Figure 4B ). R406-treated tumors in mice showed a reduction of the p-SYK (Y525/ 526)/SYK ratio ( Figure S4B ). No significant differences were detected between groups treated with R406 alone and paclitaxel alone. Body weight, physical activity, and splenic weight of mice in these groups were similar ( Figures S4C and S4D) .
Next, we determined if the paclitaxel and R406 combination was effective in suppressing intraperitoneal tumor growth in an in vivo paclitaxel-resistant ovarian cancer model. We established intraperitoneal SKOV3
Luc tumors in mice that recurred after continuous paclitaxel treatment for 7 weeks ( Figure 4D ). Compared to tumors grown in mice treated with vehicle, tumors that recurred in mice treated with paclitaxel showed higher levels of p-SYK (Y525/526) and SYK ( Figure S4E ). In primary cultures, cells from recurrent paclitaxel-treated tumors were more resistant to paclitaxel than cells from vehicle-treated tumors (Figure 4D) . The cells from the paclitaxel-resistant tumor (paclitaxel-1) were then re-injected intraperitoneally in a new cohort of mice followed by treatment with either vehicle, R406, paclitaxel or the combination. The new xenografts responded to paclitaxel initially, but regrew after week 3. Paclitaxel and R406 combination significantly reduced tumor progression in this model as compared to paclitaxel alone at week 4 and 5. R406 alone at the applied dose did not show any anti-tumor effect as compared to vehicle control (Figures 4E and 4F) . Similar to a previous report (Braselmann et al., 2006) , we did not detect gross or microscopic abnormalities in organs from these R406-treated mice. The above results indicate that the combination of paclitaxel and R406 effectively inhibited tumor growth at doses that were highly tolerable in mice.
Identification of Substrates Phosphorylated by SYK in Paclitaxel-Resistant Tumor Cells
To elucidate the molecular mechanisms by which SYK inhibition enhanced cytotoxic effects of paclitaxel, we performed stable isotope labeling by amino acids in cell culture (SILAC) (Ong et al., 2002) and compared the phosphoproteome between SKOV3TR cells treated with R406 and vehicle control. Based on two independent experiments, we identified 896 unique, differentially expressed phosphopeptides corresponding to 516 proteins (Table S2 ), more than 90% of which belonged to phosphotyrosine-containing peptides. Because we were interested in those proteins that were potentially phosphorylated by SYK, we focused on the phosphorylation sites that were downregulated (average H/L ratio <0.7) by R406 in duplicate experiments. As a result, there were 327 downregulated phosphopeptides belonging to 228 proteins. Among them, 141 peptides contained at least one acidic residue surrounding the phosphorylated Tyr, and were, therefore, considered potential substrates for SYK (Xue et al., 2012 (Xue et al., , 2013 . Several SYK substrates identified in this study, including SYK itself and PLCG1, LCK, STAT3, and a-tubulin, have been previously reported to be SYK substrates in hematopoietic cells (Couture et al., 1996; Law et al., 1996; Peters et al., 1996; Uckun et al., 2010b) . This finding indicated the robustness of our approach in identifying SYK substrates in ovarian cancer cells. Pathway analysis indicated that the identified SYK substrates participate in cell motility and organization of cytoskeleton in addition to proliferation/growth, cell death, and survival among other processes ( Figures 5A-5C ). Specifically, we identified 19 phosphosites (Table 1) in the following proteins: dynactin 2 (DCTN2), microtubule-associated protein 1B (MAP1B), microtubule-associated protein 4 (MAP4), tubulin binding co-factor B (TBCB), a-tubulin, and b-tubulin, all of which are proteins essential for microtubule dynamics. Table S3 lists phosphopeptides we identified that were also reported in B lymphocytes and breast cancer cells in a recent study that used an independent method (Xue et al., 2012) .
We selected representative SYK substrates including a-tubulin, b-tubulin, MAP4, and MAP1B for further validation because these proteins are constituents of the microtubules, and their posttranslational modification such as phosphorylation may have a direct impact on microtubule stability. Consistent with a previous report (Faruki et al., 2000) , we were able to demonstrate phosphorylation of tubulin by SYK. Importantly, our data from an in vitro kinase assay using active recombinant SYK and purified bovine microtubule-associated protein (MAPs) demonstrated that MAP1B and MAP4 were substrates of SYK ( Figure 5D ). Furthermore, co-immunoprecipitation assays demonstrated that SYK inhibitors (R406 and GS-9973) reduced the levels of Tyr-phosphorylated a-and b-tubulin, although the effect of P505-15 was modest. The induction of MAP4 and MAP1B Tyr phosphorylation by the Tyr phosphatase inhibitor pervanadate, which is known to activate SYK signaling (Faruki et al., 2000) , was suppressed by SYK inhibitors ( Figure S5A) . SYK knockdown by siRNA demonstrated a similar result (Figure S5B) . Collectively, these data show that tubulin and MAPs are direct SYK substrates.
Next, we compared the expression of total and Tyr-phosphorylated a-and b-tubulin, MAP4, and MAP1B between paclitaxel-sensitive (SKOV3 and MPSC1) and paclitaxel-resistant cells (SKOV3TR and MPSC1TR) cells. Consistent with an elevated SYK level in paclitaxel-resistant cells, Tyr-phosphorylated a-tubulin ( Figure 5E ), but not Tyr-phosphorylated b-tubulin, was upregulated in these resistant cells ( Figure S5C ). Similarly, total MAP1B and its Tyr-phosphorylated form were also upregulated in the paclitaxel-resistant cells ( Figure 5E ). In a panel of ovarian cancer cell lines, higher expression levels of ptyr-MAP1B/MAP1B were associated with less sensitivity to paclitaxel ( Figures 5F and S5D ), further suggesting the involvement of MAP1B tyrosine phosphorylation in paclitaxel resistance. Using immunohistochemistry with the antibody against phospho-a-tubulin (Y272) in 161 HGSC samples, we observed a positive correlation in staining intensity between total SYK and phospho-tubulin, and between phospho-SYK and phosphoaÀtubulin ( Figure 5G ). Two representative cases with high and low staining intensity of SYK, phospho-SYK, and phosphoa-tubulin are shown in Figure 5H . Figure 6C ). Using an in vitro microtubule binding assay, we observed that SYK phosphorylated MAP1B and MAP4 could still bind microtubule ( Figure S6 , comparing SYK 0.4 mg sample plus/minus ATP), but the presence of R406 further increased their binding.
SYK Inhibition Stabilizes Microtubules in PaclitaxelResistant Tumor Cells Co-treated with Paclitaxel
Two different approaches were used to determine whether inhibiting SYK activity would stabilize microtubules. First, we assessed two markers of microtubule stability, acetylated a-tubulin (L' Hernault and Rosenbaum, 1985; Piperno and Fuller, 1985) and detyrosinated (Glu) a-tubulin (Gundersen et al., 1984; Thompson, 1977) . Western blot analysis demonstrated that paclitaxel markedly increased both acetylated and detyrosinated tubulin levels in paclitaxel-sensitive SKOV3 and MPSC1 cells, but the effect was only modest in paclitaxel-resistant SKOV3TR and MPSC1TR cells ( Figure 7A ), indicating that the paclitaxel-resistant cells had developed a mechanism(s), presumably by increasing phosphorylation of tubulin and MAPs ( Figure 5E ), to counteract paclitaxel-induced microtubule stability. Neither acetylated nor detyrosinated tubulin levels were altered by R406 alone at the applied concentration (2.5 mM) in either paclitaxel-resistant cell line, although R406 at a higher concentration increased the levels of acetylated a-tubulin in paclitaxelsensitive and -resistant SKOV3 cells ( Figure S7A ). Compared to vehicle control, R406 alone, and paclitaxel alone, R406 and paclitaxel combination significantly increases the level of acetyl-a-tubulin in SKOV3TR and MPSCTR cells. This finding was not observed in naive cells because they are highly sensitive to paclitaxel in stabilizing microtubules at the given paclitaxel concentration ( Figure 7A ). Combination with other SYK inhibitors showed similar results ( Figure S7B ). The above findings were confirmed by immunofluorescence ( Figure S7C ). Ovarian cancer cell lines, KK, KOC7C, and OVTOKO, all of which were more resistant to paclitaxel than the naive SKOV3 and MPSC1 cells showed similar enhancement of acetylated a-tubulin in the combination treatment ( Figure 7A ). To further extrapolate the finding to an in vivo setting, we compared levels of acetyl-a-tubulin in SKOV3c.2 tumor xenografts in mice treated with paclitaxel, R406, or their combination. We observed a significant increase in the acetylated-a-tubulin level in tumor xenografts treated with combined R406 and paclitaxel ( Figure 7B ). The results of these experiments suggested that inhibition of SYK in the presence of paclitaxel augmented microtubule stabilization and cytotoxicity in paclitaxel-resistant tumor cells that were otherwise insensitive to paclitaxel.
In the second approach, we applied live-cell microscopy to record microtubule dynamics in SKOV3 and SKOV3TR cells stably transfected with GFP-a-tubulin. We used the fluorescence recovery after photobleaching (FRAP) technique to measure the speed of microtubule turnover in these cells. We observed that cells treated with R406 alone (2.5 mM) did not show any detectable changes in fluorescence recovery in SKOV3 cells. As expected, SKOV3 cells responded to paclitaxel treatment with a reduced mobile fraction and an increased half-life after photobleaching ( Figure 7C ). In contrast, SKOV3TR cells were less responsive to paclitaxel, but adding R406 (2.5 mM) to paclitaxel (30 nM) significantly reduced fluorescence recovery, including a decreased mobile fraction and an increased half-life (Figure 7D) . In SKOV3TR cells, R406 alone only slightly increased the half-life of fluorescence recovery and did not have a significant effect on mobile fractions. Thus, FRAP analysis confirmed that SYK inactivation promoted paclitaxel-induced stabilization of microtubules in paclitaxel-resistant cancer cells.
DISCUSSION
This study provides biological basis and pre-clinical evidence that targeting SYK sensitizes tumor cells to paclitaxel, especially for those that have developed paclitaxel resistance. It is likely that the paclitaxel-resistant cells with higher SYK levels and activity have developed a molecular mechanism that counteracts paclitaxel-mediated microtubule stabilization, thus reducing paclitaxel-induced cytotoxicity. Our finding validates a previous hypothesis that modulating microtubule stability can enhance the cytotoxic response of ovarian cancer cells to paclitaxel (Ahmed et al., 2011) . Indeed, by analyzing the SYK substrates in paclitaxel-resistant ovarian cancer cells, we identified tubulin and MAPs as substrates of SYK, raising the possibility that SYK inactivation affects microtubule dynamics. The role of SYK in cancer therapeutics has also been reported by others. SYK activity has been demonstrated to play an important role in imatinib or nilotinib resistance in CML (Gioia et al., 2011) and the pentapeptide mimic targeting the substrate binding site of SYK has an anti-tumor effect on chemotherapy-resistant relapsed B-precursor leukemia cells (Uckun et al., 2010a) .
How SYK tyrosine phosphorylation affects the functions of tubulin and MAPs is not clear. Faruki et al. reported that tubulin, upon SYK-mediated phosphorylation, was able to assemble into microtubules (Faruki et al., 2000) , but the effects on microtubule (legend continued on next page) dynamics remain to be determined. This is further complicated by SYK-mediated phosphorylation on many microtubule interacting proteins such as MAP1B and MAP4 that also play critical roles in microtubule dynamics (Krisenko et al., 2014) . MAP1B and MAP4 bind to microtubules and facilitate their polymerization and stabilization. Because serine phosphorylation of MAPs has been shown to decrease interactions of MAPs and microtubules, promoting microtubule dynamics (Chang et al., 2001; Goold et al., 1999; Trivedi et al., 2005) , it is likely that tyrosine phosphorylation by SYK has a similar effect because SYK phosphorylates MAP4 at tyrosine Y1001, which resides in the conserved microtubule binding domain of MAP4.
The observation that R406 alone is sufficient to reduce cellular proliferation at doses that do not significantly affect microtubule stability suggests that the anti-proliferative activity of R406 can also be attributed to inactivation of SYK-regulated tumor-promoting pathways. By analyzing the SILAC data, we also identified several SYK substrates that belong to canonical tumor-promoting pathways. These include STAT3, which has been reported as a substrate for SYK in hematopoietic cells (Uckun et al., 2010b) . R406 markedly reduces phosphorylation of STAT3 tyrosine residues Y704 and Y705, the latter of which is associated with STAT3 activity and its anti-apoptotic effect (Chen et al., 2008) . In addition, we identified a group of SYK substrates including PIK3R1/2 and adaptor proteins, GAB1/2 and SHC, that are involved in the growth factor/PI3K signaling. These proteins generally couple signaling among activated growth factor receptors upon ligand binding such as VEGF, EGF, IGF1, and HGF (Holgado-Madruga and Wong, 2003) with PI3K signaling pathway, which has been known to participate in chemoresistance (Koti et al., 2013) . Thus, our data suggest that the anti-tumor effects of inactivating SYK come from two broad mechanisms-stabilizing microtubules and suppressing growth-promoting signaling pathways. For the latter, we demonstrated that R406 suppressed phosphorylation of other SYK substrates including pSTAT3 and pAKT of which phosphorylation was reported to protect tumor cells from chemotherapyinduced cytotoxicity. However, unlike the synergistic effect on microtubule stability, adding paclitaxel did not further reduce their phosphorylation levels (data not shown). Thus, we focus on the biological effects of targeting SYK signaling on microtubule dynamics.
Microtubules have been well established as a major target for cancer treatment. The anti-mitotic microtubule-targeting drugs include (1) vinca alkaloids (vinblastine, vincristine, vindesine, and vinorelbine) that bind to a-and b-tubulin heterodimers, preventing their incorporation into microtubules and microtubule polymerization; and (2) microtubule-stabilizing agents such as paclitaxel and docetaxel (collectively known as taxanes) that directly interact with and stabilize microtubules (Liu et al., 2014) . Thus, SYK inhibitors represent another group of drugs that affect microtubules through regulating phosphorylation of tubulin and MAPs. The different mechanisms used by SYK inhibitors and paclitaxel may explain their synergistic effect in cancer cells, especially in those that developed paclitaxel resistance. Our results may have important clinical ramifications because taxanes are frequently used in treating several major types of cancer such as breast and lung carcinoma in addition to ovarian carcinoma. Because development of taxane resistance is common, introduction of regimens to overcome paclitaxel resistance is an unmet need.
The main SYK inhibitor used in this study is R406, the active form of fostamatinib (also known as R788), which is orally administrable and highly tolerable when used in late-phase clinical trials of rheumatoid arthritis, auto-immune diseases, and hematologic malignancies (Friedberg et al., 2010; Podolanczuk et al., 2009; Weinblatt et al., 2010) . Several clinical trials of fostamatinib have reported its pharmacokinetics and safety profile at a range of doses up to 250 mg twice daily (Friedberg et al., 2010; Weinblatt et al., 2008) . The plasma concentration reported from these studies ranges between 300 and 1,800 ng/ml (molar concentration 0.5-2.9 mM), which is relevant to the R406 concentrations used in our experiments. Therefore, the availability of fostamatinib and the minimal overlap between observed clinical toxicities of fostamatinib and paclitaxel would facilitate the translation of the current pre-clinical study (Weinblatt et al., 2010) . For example, results of our study warrant determining the benefit of adding fostamatinib to the weekly paclitaxel regimen used in treating recurrent ovarian cancer.
Finally, the current study focuses on demonstrating the direct function of SYK on microtubule constituents and concludes that the major mechanism for SYK inhibitors to sensitize paclitaxel effects is through altering the SYK-MAP-tubulin axis. Because SYK may have multiple roles in promoting tumor progression, it should not be construed that other SYK-regulated microtubule-independent pathways are not involved in paclitaxel resistance. In fact, this study also validated that both STAT3 and AKT were the substrates of SYK and their inhibition can enhance cytotoxicity of chemotherapeutic agents, although the underlying mechanisms have yet to be further elucidated (Lin et al., 2015; Abubaker et al., 2014) .
EXPERIMENTAL PROCEDURES
Detailed materials and methods are provided in the Supplemental Experimental Procedures. 
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Maryland. All studies were Johns Hopkins University School of Medicine Institutional Review Board exempt because no protected health information was used. To compare the expression levels of SYK in paired recurrent post-chemotherapy ovarian HGSC and their primary untreated tumors, we performed immunohistochemistry. The primary tumors from HGSC patients were optimally debulked to a residual tumor volume less than 1 cm, and all patients received standard carboplatin and paclitaxel therapy for three to six cycles. Paraffin tissues were arranged in tissue microarrays to facilitate immunohistochemistry and to ensure that tissues were stained under the same conditions. The 214 effusions were obtained from the Norwegian Radium Hospital (177 peritoneal, 37 pleural) were from 211 patients (two patients had two effusions) diagnosed with serous carcinoma in the years 1998-2005. One hundred twenty-three effusions were collected at diagnosis prior to chemotherapy, whereas 88 effusions were post-chemotherapy specimens, collected at disease recurrence. Data regarding previous chemotherapy were unavailable for three patients. Figure S6 .
the primary antibody at 4 C overnight and the appropriate secondary antibody at room temperature for 30 min. Colorimetric development was detected by the EnVision+System (DAKO). Sections were counterstained with hematoxylin, and immunoreactivity was scored using the H score system by two investigators based on the percentage of positively stained cells and the intensity of staining, which ranged from 0 to 3+. A composite score was determined by multiplying the intensity and extent scores.
Xenograft Mouse Tumor Models
Two models were used in this study. Fluorescence Recovery after Photobleaching SKOV3 and SKOV3TR cells were transfected with a plasmid expressing GFP-a-tubulin, and multiple positive clones were pooled for further expansion. Photobleaching procedures were performed using a confocal laser-scanning microscope. The dynamics parameters recorded from FRAP included the fraction of microtubules that recovered within 2 min after photobleaching (mobility fraction), and the time it took for half of the mobile fraction of microtubules to recover (t 1/2 ). Regions of interest were bleached for 10 s followed by 2 min of observation, with image acquisition every 2 s. At least 12-15 observations were recorded per sample, and the recovered fluorescence intensities were normalized against background and unbleached regions within the cell of interest (Daniels et al., 2009 ). Figure 2D . 
SYK constructs and Tetracycline Off inducible system
The Tet-Off inducible system (Clontech) was utilized to assess the effect of SYK expression on paclitaxel sensitivity. SKOV3 cells that constitutively expressed tTA (tetracycline-controlled transactivator) were transduced with pLVX-Tight-Puro-SYK-WT and pLVX-Tight-Puro-SYK-130E (kind gift from Dr. Robert Geahlen, Purdue University). SYK-WT and SYK-130E 15 activated mutant were expressed upon the binding of tTA to the tetracycline-responsive element in the absence of inducer (doxycycline).
Immunofluorescence staining
Paclitaxel sensitive and resistant SKOV3 and MPSC1 cells were seeded on chamber slides, treated with paclitaxel, R406, or their combination. The cells were then fixed with 4%
paraformaldehyde and then incubated with anti-acetyl-α-tubulin (Lys40) (D20G3) rabbit monoclonal antibody (#5335; CST) or anti-Glu-tubulin rabbit polyclonal antibody (AB3201; Millipore) for 2 hr, followed by Cy3-(Sigma) or Alexa Flour 488-conjugated anti-rabbit antibody (CST). Cell nuclei were counterstained with DAPI (Sigma).
SYK knockdown and SYK inhibitors
Two distinct shRNAs targeting SYK (shSYK2 and shSYK4) were engineered and packaged using the lentivirus delivery system. The shRNA plasmids targeting SYK (TTCCCTGTCTTGTCTTTGTCG and TTCTTGAGATTATTCCACCCG) and the control plasmid (pLKO.1-puro vector-only) were obtained from Thermo Scientific (TRC Lentiviral shRNA). Lentivirus that expressed shRNA was produced using HEK293FT cells (Invitrogen) with the packaging system, pSPAX2 (Addgene plasmid 12260) and pMD2.G (Addgene plasmid 12259). SYK knockdown were also performed using two independent siRNAs targeting SYK (Silencer® Select s13680 and s13681, Life Technologies) and one control siRNA (Silencer® Select Negative Control No. 1) that were transfected using Lipofectamine RNAiMAX (Invitrogen). SYK inhibitors R406, PRT062607 (P505-15) and GS-9973 were purchased from SelleckChem.
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Cell cycle measurements in situ
Low magnification (10x) micrographs of cells stained with H33342 were acquired using a DSQiMc camera mounted onto an epifluorescence microscope (Nikon, T300) equipped with a motorized stage (Prior Scientific), and controlled by the Nikon NIS Elements software. Using custom software developed in MatLab, individual nuclei were segmented, and the summation of the intensities within defined nuclear regions were calculated after correction of the images for non-uniformities in the illumination fields, (W- C Chen et. al. 2013 , A.Chambliss et. al. 2013 ).
Using these intensity output distributions as a readout of DNA content, similar to those derived from flow cytometry results, cells were categorized into cell cycle phases based on the intensity values: low intensity-first peak (G0/G1), high intensity-second peak (G2/M), and median intensity (S) (Wu et. al., 2011) .
Immunoprecipitation and Western Blotting
Protein lysates were obtained by lysing cells using either RIPA buffer or 1% Triton-X buffer supplemented with protease and phosphatase inhibitors (Roche). The following antibodies, anti-MAP1B (N-19) (Santa Cruz sc-8970) and anti-α-tubulin (Sigma T5168), were used for immunoprecipitation by Dynabeads®. Proteins were separated by 4-15% sodium dodecyl sulfate polyacrylamide gel electrophoresis (Mini-Protean TGX Gels, Bio-Rad), and transferred onto polyvinylidene difluoride membranes (Trans-Blot®, BioRad) using a semi-dry transfer apparatus C6 L-Lysine-2HCl (heavy media) (Cambridge Isotope Laboratories, Andover, MA) for a minimum of 9 cell doublings. Cells grown in light media were incubated with DMSO and the cells cultured in heavy media were incubated with 2.5 μM R406 for 2 hr and lysed in 20 mM HEPES pH 8.0, 9 M urea, 1 mM sodium orthovanadate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate buffer. Equal amounts of protein were mixed and subjected to tryptic digestion as described earlier (Harsha et al., 2008) . Briefly, the pooled lysates were reduced with 5 mM dithithreitol and alkylated with 10 mM Iodoacetamide. The samples were then diluted and digested with TPCK treated trypsin (Worthington) overnight at room temperature. The peptide mixture was acidified using 1% trifluoroacetic acid, desalted on a C18 Sep-Pak cartridge, and lyophilized. Immunoaffinity purification of phosphopeptides was carried out using P-Tyr-100 beads (PTMScan Tyr Motif IAP beads) (Cell Signaling Technologies, Danvers, MA) as previously described (Rush et al., 2005) .
All immunoaffinity-enriched phosphopeptides were analyzed by an LTQ-Orbitrap Elite mass spectrometer (Thermo Electron, Bremen, Germany) interfaced with an Easy-nLC II nanoflow liquid chromatography system (Thermo Scientific, Odense, Southern Denmark) and resolved on an analytical column (75 µm x 20 cm). Data acquisition with full scans at 350-1800 m/z was carried out using an Orbitrap mass analyzer at a mass resolution of 120,000 at 400 m/z.
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The 15 most intense precursor ions from a survey scan were selected for MS/MS fragmentation using HCD fragmentation with 35% normalized collision energy, and were detected at a mass resolution of 30,000 at 400 m/z. Dynamic exclusion was set for 30 seconds with a 10 ppm mass window. The mass spectrometry data were searched using MASCOT (Version 2.2.0) and SEQUEST algorithms against a human RefSeq database (version 59 containing 33,832 entries) using Proteome Discoverer 1.4, 1.3.0.265 (DBVersion: 76) (Thermo Fisher Scientific, Bremen, Germany). MS/MS spectra were searched with a precursor mass tolerance of 10 ppm and fragment mass tolerance of 0.05 Da. Trypsin was specified as protease with maximum two missed cleavages allowed. The minimal peptide length was specified to be 6 amino acids. The data were searched against a decoy database, and the false discovery rate was set to 1% at the peptide level. The ratio of heavy/light for each phosphopeptide-spectrum match (phosphoPSM) was calculated by the quantitation node, and the probability of phosphorylation for each Tyr/Ser/Thr site on each peptide was determined from the PhosphoRS 3.1 node in the Proteome
Discoverer. For further analysis, we only considered phosphopeptides with > 75% localization probability. The MS and MS/MS spectra for all ratios corresponding to heavy/light <0.7 from both replicates were manually verified, and defined potential SYK substrates.
Microtubule binding assay
Microtubule binding assay using a microtubule spin-down kit (Cytoskeleton, Denver, CO) was employed to measure the affinity of MAPs to microtubules. Briefly, microtubules were assembled in a general tubulin buffer (80 mM PIPES, pH 7.0, 2 mM MgCl2, and 0.5 mM EGTA) incubated at 35°C for 20 min in the presence of GTP and paclitaxel. Purified MAPs were incubated with SYK in the presence or absence of R406 (37°C, 1 hr) prior to incubation with 19 assembled microtubule for 30 min. Microtubules and the associated proteins were then pelleted at 100,000 × g (20 min, 4°C) through a 50% glycerol cushion buffer. Prior spin-down experiments confirmed that MAPs did not pellet without microtubule under these conditions.
The supernatant and pellet separately were dissolved in Laemmli loading buffer, and run on SDS-PAGE gel for analysis.
